Slide 1: H1 2022 Results
H1 2022 Results Matthias Gaertner, CEO Falk Neukirch, CFO August 11, 2022
Slide 2: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2022, growth story, ESG 4 Appendix 2
Slide 3: Highlights H1: Again, KPIs at record levels
Executive summary Highlights H1 : Again, KPIs at record levels Implementation of the growth strategy on track: • Already synergy and cross-selling effects from the NewCo Pharma integration – substantial strengthening of market position in the area of compounding • Additional compounding capacities i
Slide 4: Growth and earnings achieve record levels
Executive summary Growth and earnings achieve record levels Revenue €m EBITDA pre¹ €m 393 399 14.1 14.3 369 354 319 316 10.2 9.5 10.0 8.8 163 160174 130 4.8 4.3 3.8 3.6 3.6 2.7 margin 2.5 2.2 3.0 2.8 2.7 2.9 2.3 1.6 1.9 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2020 2021 2022 2020
Slide 5: H1 2022 – Continuous and sustainable growth
Executive summary H1 2022 – Continuous and sustainable growth Revenue EBITDA pre¹ in €m in €m + 24.8% + 55.9% 792 635 18.3 28.5 H1 2021 H1 2022 H1 2021 H1 2022 ¹ EBITDA without extraordinary expenses: adjusted for extraordinary expenses for stock options & M&A activities 5
Slide 6: H1 2022 – Split by segments: Share of PST significantly increased
Executive summary H1 2022 – Split by segments: Share of PST significantly increased Revenue by segment EBITDA pre by segment 14% 43% 86% 57% Pharmaceutical Supply Pharmaceutical Supply Patient-specific Therapies Patient-specific Therapies 6
Slide 7: Excellent geographic coverage through strong nationwide network of partners and own compounding facilities
Executive summary Excellent geographic coverage through strong nationwide network of partners and own compounding facilities • 7 GMP1 / blistering labs Hamburg • 2 warehouses Berlin (HQ) Osnabruck • Around 600 specialized partner Berlin pharmacies Cologne • Around 320,000 individualized preparations
Slide 8: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2022, growth story, ESG 4 Appendix 8
Slide 9: H1 2022 – Strong financials driven by external growth
Financial overview H1 2022 – Strong financials driven by external growth In € million H1 2022 H1 2021 ∆% Revenue 792.2 634.9 24.8% • Strong revenue growth mainly driven Gross profit 53.4 32.4 64.8% by NewCo Pharma acquisition gross margin in % 6.7 5.1 • Disproportionately increased gross EBITDA pre1
Slide 10: H1 2022 – Strong organic and inorganic revenue growth
Financial overview H1 2022 – Strong organic and inorganic revenue growth Inorganic H1 YoY Revenue in €m H1 2021 Organic H1 2022 (NewCo only) Pharmaceutical Supply 603.6 51.8 27.1 682.5 • Successful integration of NewCo Patient-specific Therapies 31.0 3.2 75.3 109.5 Pharma led to revenue contribution
Slide 11: H1 2022 – EBITDA pre driven by acquisition of NewCo Pharma
Financial overview H1 2022 – EBITDA pre1 driven by acquisition of NewCo Pharma Inorganic H1 YoY EBITDA pre1 in €m H1 2021 Organic H1 2022 (NewCo only) Pharmaceutical Supply 15.2 0.2 2.0 17.5 • EBITDA pre of PS and PST segments grew mainly inorganically but also Patient-specific Therapies 4.0 0.2 9.0
Slide 12: H1 2022 – Strong Group margin, mainly as a result of increased PST share
Financial overview H1 2022 – Strong Group margin, mainly as a result of increased PST share Pharmaceutical Patient-specific Internal Services and Group Supply ‚PS‘ Therapies ‘PST’ IFRS consolidation In € million H1 2022 H1 2021 H1 2022 H1 2021 H1 2022 H1 2021 H1 2022 H1 2021 Revenue1 682.5 603.6 109
Slide 13: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2022, growth story, ESG 4 Appendix 13
Slide 14: Forecast FY 2022 confirmed (1/2)
Guidance 2022 Forecast FY 2022 confirmed (1/2) Revenue EBITDA pre2 Comments in €m in €m Forecast confirmed despite ongoing + 6.8 - 17.9% + 35.3 - 50.9% global uncertainties Revenue expected to reach upper end of the range of €1.45-1.6bn 1,450 52 - 58 EBITDA pre1 range remains – 1,600 unchanged: €52-
Slide 15: Forecast FY 2022 confirmed (2/2) – Main assumptions
Guidance 2022 Forecast FY 2022 confirmed (2/2) – Main assumptions + The acquisition of NewCo Pharma will significantly contribute to external growth and to significant EBITDA pre margin increase + Synergy effects as a result of the integration of Cranach Pharma & Newco Pharma: • Especially in purcha
Slide 16: Medios' growth strategy
Growth strategy & ESG Medios’ growth strategy • Compounding capacities to triple as a result of • Compounding from partner pharmacies to be new labs in Berlin potentially integrated into Medios’ labs • Advance market penetration through innovative • Add further labs in case of geographical fit and/
Slide 17: Implementation of ambitious ESG strategy 2025 on track
Growth strategy & ESG Implementation of ambitious ESG strategy 2025 on track Implementation process of IT-based ESG-platform 2023 and beyond advanced • Sustainability reporting in full accordance with GRI1 Corporate Governance: Successful AGM 2022: for FY 2022 Among others, modernization of the Arti
Slide 18: Agenda
1 Executive summary 2 Financial overview 3 Guidance 2022, growth story, ESG 4 Appendix 18
Slide 19: H1 2022 - Key figures (1/2)
Appendix H1 2022 - Key figures (1/2) in € thousand H1 2022 H1 2021 ∆ in % Q2 2022 Q2 2021 ∆ in % Revenue 792,179 634,927 24.8% 399,224 319,019 25.1% Pharmaceutical Supply 682,456 603,560 13.1% 343,252 303,932 12.9% Patient-Specific Therapies 109,484 31,047 252.6% 55,875 14,912 274.7% Services 238 32
Slide 20: H1 2022 - Key figures (2/2)
Appendix H1 2022 - Key figures (2/2) in € thousand H1 2022 H1 2021 ∆ in % Q2 2022 Q2 2021 ∆ in % Earnings per share (in €) Undiluted 0.42 0.32 31.3% 0.21 0.17 23.5% Diluted 0.42 0.31 35.7% 0.21 0.17 23.5% Investments (CAPEX) 2,864 5,760 -50.3% 721 3,131 -77.0% Cash flow from operating activities 9,9
Slide 21: Q2 2022 – Record quarter resulting from NewCo acquisition supported by organic growth
Financial overview Q2 2022 – Record quarter resulting from NewCo acquisition supported by organic growth Inorganic Q2 YoY Revenue in €m Q2 2021 Organic Q2 2022 (NewCo only) Pharmaceutical Supply 303.9 25.7 13.7 343.3 • Inorganic growth driven by NewCo Patient-specific Therapies integration 14.9 2.5
Slide 22: Q2 2022 – EBITDA pre growth driven by acquisition
Financial overview Q2 2022 – EBITDA pre growth driven by acquisition Inorganic Q2 YoY EBITDA pre1 in €m Q2 2021 Organic Q2 2022 (NewCo only) Pharmaceutical Supply 8.3 -0.2 1.1 9.1 • Slight organic decrease in PS Patient-specific Therapies 1.7 0.3 4.3 6.4 • Successful integration of NewCo Services Ph
Slide 23: Q2 2022 – Strong Group margin, mainly as a result of increased PST share
Financial overview Q2 2022 – Strong Group margin, mainly as a result of increased PST share Pharmaceutical Patient-specific Internal Services and Group Supply ‚PS‘ Therapies ‘PST’ IFRS consolidation In € million Q2 2022 Q2 2021 Q2 2022 Q2 2021 Q2 2022 Q2 2021 Q2 2022 Q2 2021 Revenue1 343.3 303.9 55.
Slide 24: Contact
Contact Claudia Nickolaus Head of Investor & Public Relations, ESG Communications Phone +49 30 232 566 800 c.nickolaus@medios.ag 24
Slide 25: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C
Slide 26: H1 2022 Results
H1 2022 Results Matthias Gaertner, CEO Falk Neukirch, CFO August 11, 2022